- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Processa Pharmaceuticals Inc (PCSA)
The Processa Pharmaceuticals share price today is 2.6100, view NASDAQ PCSA stock exchange data. Track the latest Processa Pharmaceuticals share price with real-time updates on PCSA stock performance including market cap, day range, 52-week range and dividend yield. Access PCSA charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.5700
2.8899
52 wk Range
1.7600
19.6348
PCSA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.57002.8899
52 wk Range
1.760019.6348
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PCSA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
25.0000
Upside
+857.85%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Sian Bigora, Processa CDO, buys $5,341 in stock
- Investing.com
- Sian Bigora, Processa CDO, buys $5,341 in stock
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 25.0000
(+857.85% Upside)
Earnings
Latest Release
07-05-2026
EPS / Forecast
-1.29 / -0.06
Revenue / Forecast
-- / --
Compare PCSA to Peers and Sector
Metrics to compare | PCSA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPCSAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −6.5x | −0.5x | |
PEG Ratio | −0.01 | −0.40 | 0.00 | |
Price/Book | 2.7x | −1.5x | 2.6x | |
Price / LTM Sales | - | 1.7x | 3.1x | |
Upside (Analyst Target) | - | 86.9% | 55.1% | |
Fair Value Upside | Unlock | 6.7% | 7.2% | Unlock |
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Processa Pharmaceuticals (PCSA) Share Price Today?
The Processa Pharmaceuticals share price today is 2.6100.
What is the current Processa Pharmaceuticals (PCSA) share price and day range?
As of 20-05-2026, the Processa Pharmaceuticals share price is 2.6100, with a previous close of 2.7500. The share price has ranged from 2.5700 to 2.8899 today, while the 52-week range spans from 1.7600 to 19.6348.
What Is the Processa Pharmaceuticals Market Cap?
As of today, Processa Pharmaceuticals market cap is 7.0200M.
What Is the Processa Pharmaceuticals (PCSA) Share Price Target?
The average 12-month share price target for Processa Pharmaceuticals is 25.0000, with a high estimate of 25 and a low estimate of 25. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +857.85% Upside potential.
What Is Processa Pharmaceuticals's Earnings Per Share (TTM)?
The Processa Pharmaceuticals EPS (TTM) is -7.5373.
From a Technical Analysis Perspective, Is PCSA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Processa Pharmaceuticals Trade On?
Processa Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Processa Pharmaceuticals?
The stock symbol for Processa Pharmaceuticals is "PCSA."
How Many Times Has Processa Pharmaceuticals Stock Split?
Processa Pharmaceuticals has split 4 times.
How Many Employees Does Processa Pharmaceuticals Have?
Processa Pharmaceuticals has 12 employees.
What Is the PCSA Premarket Price?
PCSA's last pre-market stock price is 2.8000. The pre-market share volume is 390.0000, and the stock has changed by 0.0500, or 1.8200%.
What Is the PCSA After Hours Price?
PCSA's last after hours stock price is 2.6000, the stock has changed by -0.0100, or -0.3800%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.